HARBOUR BIOMED
Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.
HARBOUR BIOMED
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2016-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.harbourbiomed.com
Total Employee:
51+
Status:
Active
Contact:
+86-21-51370990
Email Addresses:
[email protected]
Total Funding:
312.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Domain Not Resolving Mobile Non Scaleable Content Nginx Euro Microsoft Azure DNS PHP
Similar Organizations
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
I-Mab Biopharma
I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.
IASO Biotherapeutics
IASO Biotherapeutics is a biopharmaceutical company focused on the development of cell therapies in the field of oncology.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
InventisBio
InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.
Lianchuang Biomedicine
Lianchuang Bio is a pharmaceutical company that offers R&D, production, and marketing of advanced pharmaceutical intermediates.
Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing novel therapies for acute and chronic gastrointestinal complications.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-12-19 | Harbour Antibodies | Harbour Antibodies acquired by Harbour Biomed | N/A |
Investors List
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Series C - Harbour Biomed
Greater Bay Area Homeland Development Fund
Greater Bay Area Homeland Development Fund investment in Series C - Harbour Biomed
Octagon Capital Partners
Octagon Capital Partners investment in Series C - Harbour Biomed
Country Garden
Country Garden investment in Series C - Harbour Biomed
OrbiMed
OrbiMed investment in Series C - Harbour Biomed
ShenZhen GTJA Investment Group
ShenZhen GTJA Investment Group investment in Series C - Harbour Biomed
SK Holdings
SK Holdings investment in Series B - Harbour Biomed
Zhejiang University
Zhejiang University investment in Series B - Harbour Biomed
Greater Bay Area Homeland Development Fund
Greater Bay Area Homeland Development Fund investment in Series B - Harbour Biomed
GIC
GIC investment in Series B - Harbour Biomed
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-14 | Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer |
| 2021-12-02 | Harbour BioMed Appoints Mr. Weihao Xu as Chief Strategy Officer |
| 2021-07-20 | Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer |
Official Site Inspections
http://www.harbourbiomed.com Semrush global rank: 3.95 M Semrush visits lastest month: 3.16 K
Unable to get host informations!!!
More informations about "Harbour Biomed"
和铂医药 - Harbour BioMed - HBM Holdings
The Harbour Mice ® Platform Technology, which includes both the H2L2 and HCAb transgenic mice platforms, have been widely used by over 40 companies and academic institutions. The platforms were engineered to produce high …See details»
Harbour BioMed - LinkedIn
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on …See details»
Harbour Biomed - Crunchbase Company Profile
Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and …See details»
Corporate Governance - HBM Holdings - test.harbourbiomed.com
He has also been a member of the European Molecular Biology Organization since 1976. Xiaoping Ye Independent non-executive Director. Mr. Xiaoping Ye, Ph.D. (叶小平), in an …See details»
Harbour BioMed - Overview, News & Similar companies - ZoomInfo
Aug 8, 2023 Harbour BioMed has announced that Humphrey Gardner has joined the organization as Chief Medical Officer. Previously, Gardner served as Chief Medical Officer for …See details»
Harbour BioMed - Pharma Industry Review
Harbour BioMed is a multinational clinical stage biopharmaceutical company developing next-gen therapeutics in the areas of immuno-oncology and immunological diseases.See details»
Harbour BioMed Announces Business Progress and Update
Feb 13, 2025 Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 13, 2025 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical company committed to …See details»
Harbour BioMed Appoints Michael D. Patten as Chief Strategy …
Mar 11, 2025 CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company …See details»
Harbour BioMed Acquires Harbour Antibodies to Create Global, …
Dec 19, 2016 CAMBRIDGE, Mass. & SHANGHAI & ROTTERDAM, The Netherlands–(BUSINESS WIRE)–Harbour BioMed, a recently established Shanghai-based …See details»
Harbour BioMed Announces Business Progress and …
Feb 14, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization...See details»
和铂医药与英矽智能达成战略合作，共同推进AI驱动抗体药物研发
中国上海，美国马萨诸塞州剑桥，荷兰鹿特丹 – 2025年2月20日 . 和铂医药（股票代码：02142.hk），一家专注于免疫性疾病及肿瘤领域创新抗体疗法发现、开发及商业化的全球生 …See details»
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business …
Nov 14, 2024 Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024 . Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical company committed to …See details»
Harbour BioMed Enters into Global Strategic Collaboration with ...
1 day ago Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in …See details»
Harbour BioMed Enters into Global Strategic Collaboration with ...
1 day ago Shanghai, CN, Cambridge, MA, Rotterdam, NL – March 21, 2025 . Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, …See details»
Harbour BioMed Enters into Global Strategic Collaboration with ...
1 day ago SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company …See details»
Harbour BioMed and Insilico Medicine Achieve Strategic …
Feb 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization...See details»
Harbour BioMed Launches Élancé Therapeutics to Advance
Mar 12, 2025 CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 12, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company …See details»
Harbour BioMed partners with Insilico to accelerate AI-powered …
Feb 21, 2025 Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody …See details»
Harbour BioMed and Insilico Medicine Achieve Strategic …
Feb 20, 2025 Cambridge, MA, Rotterdam, NL, Shanghai, CN — February 20, 2025 . Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to …See details»
Harbour BioMed Enters into Global Strategic Collaboration with ...
1 day ago SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company …See details»